The cost reduction comes as the Biden administration previously capped insulin costs at $35 per month for seniors and others on Medicare with diabetes. Arrives Weekly Get Our Newsletter Get a brief on the top business stories of the week, plus CEO interviews, market updates, tech and money ...
and puts the drug's value roughly on par with another agent recently approved to treat such patients,sacubitril/valsartan(Entresto), which carries a cost-effectiveness value of about $45,000/QALY.
Sacubitrilvalsartan has been proven to be effective in reducing the risks of hospitalization for HF in ADHF. When to initiate sacubitrilvalsartan in ADHF to make it the most cost-effective in China remains unclear. Methods: A lifetime Markov model with a 1-month cycle ...